Outlook for the NGS-Based RNA-Sequencing Market to 2030: Analysis of Market Size, CAGR, Trends, and Forecast

The Business Research Company’s NGS-Based RNA-Sequencing Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, October 26, 2026 /EINPresswire.com/ — The field of NGS-Based RNA-Sequencing is rapidly evolving and gaining significant traction within the broader landscape of genomic technologies. With remarkable advancements and growing applications in medical research and clinical diagnostics, this market is on track to achieve impressive milestones in the coming years. Below is a detailed exploration of the market’s size, key drivers, regional dynamics, and competitive environment shaping its future.

Market Size and Expected Growth Trajectory in the NGS-Based RNA-Sequencing Sector
The NGS-Based RNA-Sequencing market is projected to exceed $11 billion by 2030. This segment forms a substantial part of the larger Next Generation Sequencing market, which itself is anticipated to reach close to $28 billion by that year. Notably, the RNA-sequencing segment will represent roughly 40% of this parent market. Within the expansive Medical Equipment industry, expected to be valued at $1,176 billion by 2030, the NGS-Based RNA-Sequencing market will make up nearly 1% of the total market worth.

Request A Free Sample Of The NGS-Based RNA-Sequencing Market Report
https://thebusinessresearchcompany.com/sample_request?id=94241890&type=smp&name=NGS-Based%20RNA-Sequencing%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Asia-Pacific to Lead the NGS-Based RNA-Sequencing Market Regionally by 2030
By 2030, Asia-Pacific is set to emerge as the dominant region in the NGS-Based RNA-Sequencing market, with a valuation of $3.7 billion. From $1.3 billion in 2025, the market here is anticipated to grow at a robust compound annual growth rate (CAGR) of 23%. This rapid expansion is driven by increased governmental funding in genomics and precision medicine, higher adoption rates of next-generation sequencing systems in both research and clinical laboratories, intensified biopharmaceutical R&D activities, and the rising incidence of cancer and genetic diseases that require transcriptomic analysis. Additionally, growing collaborations among academic institutions, healthcare providers, and sequencing technology developers are accelerating advancements in RNA-focused research and diagnostics.

United States to Maintain Its Position as the Largest National Market in 2030
The United States is forecasted to remain the largest single-country market worldwide for NGS-Based RNA-Sequencing in 2030, valued at $3.2 billion. The market is expected to advance from $1.2 billion in 2025, reflecting a CAGR of 22%. Key growth factors include the expanding role of RNA sequencing in oncology and rare disease research, increased funding toward genomic medicine initiatives, a strong presence of leading sequencing platform manufacturers and bioinformatics firms, integration of AI-driven transcriptomic data analysis, and a growing demand for personalized therapies fueled by advanced molecular profiling technology.

Access The Detailed NGS-Based RNA-Sequencing Market Report Here
https://thebusinessresearchcompany.com/report/NGS-based-RNA-sequencing-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Dominant Product and Service Segments Within the NGS-Based RNA-Sequencing Market
Breaking down the market by product and service, sequencing platforms and consumables will be the largest segment, accounting for approximately 50% or $6 billion of the total market by 2030. This segment benefits from the rising deployment of high-throughput sequencing instruments, steady demand for sequencing reagents and consumables, increased adoption of automated library preparation workflows, and broader transcriptomics applications in research and clinical contexts. Moreover, ongoing technological improvements continue to enhance sequencing accuracy, throughput, and cost-effectiveness, further supporting this segment’s growth.

Technology Types Driving the NGS-Based RNA-Sequencing Market
The market is segmented by sequencing technologies, including sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. These varied methods cater to diverse research and clinical needs, each bringing distinct advantages in terms of speed, accuracy, and data output.

Application Areas Defining Market Demand
In terms of applications, the NGS-Based RNA-Sequencing market is categorized into expression profiling analysis, small RNA sequencing, and de novo transcriptome assembly. These applications provide critical insights across biological research and clinical diagnostics, driving demand for RNA sequencing solutions.

End User Landscape in the NGS-Based RNA-Sequencing Market
The major users of NGS-Based RNA-Sequencing technologies include research and academic institutions, pharmaceutical and biotechnology companies, and other specialized end users. Each group leverages these tools for advancing scientific discoveries, drug development, and clinical testing.

Projected Annual Growth Rate Leading to 2030
The market is expected to grow at a compound annual growth rate (CAGR) of 22% through 2030, reflecting strong and sustained demand across various sectors.

Market Drivers Accelerating the Expansion of NGS-Based RNA-Sequencing
One of the primary growth drivers is the rising adoption of precision medicine and personalized healthcare. More healthcare providers are incorporating transcriptomic profiling into clinical workflows to understand disease biology at an individual level, enabling optimized treatment and monitoring strategies. RNA sequencing’s capability to analyze gene expression comprehensively supports these personalized approaches, which are becoming increasingly valued across healthcare systems. This trend is anticipated to contribute about 1.5% annual growth to the market.

Another significant factor propelling market growth is the surge in research focused on cancer and genetic disorders. Transcriptomic studies are expanding rapidly to identify new biomarkers, regulatory pathways, and molecular mechanisms related to various diseases. Enhanced collaborations among biotech firms, pharmaceutical companies, and academic researchers are accelerating translational research and driving therapeutic innovation. The growing availability of large genomic datasets further amplifies RNA sequencing’s role in disease investigations, expected to add around 1.0% annual growth to the market.

Technological Innovations Bolstering Market Expansion
Continuous advancements in sequencing platforms are playing a crucial role in the market’s growth. Innovations in sequencing hardware, automation, and integrated informatics are streamlining workflows and reducing the time needed for transcriptomic analyses. Improved scalability, higher sequencing performance, and more user-friendly systems are facilitating wider adoption in both research and clinical settings. Consequently, these technological improvements are predicted to contribute roughly 0.8% annual growth.

Key Market Segments Offering Promising Opportunities
The most lucrative opportunities are expected within sample preparation products, sequencing platforms and consumables, sequencing services, as well as data analysis, storage, and management segments. Combined, these areas are forecasted to generate over $7.7 billion by 2030. Growth here is fueled by the increasing use of multi-omics research, expanded clinical applications of transcriptomics, investments in laboratory automation and bioinformatics infrastructure, growing demand for high-throughput workflows, and ongoing innovations in sequencing chemistries and data management. This expanding ecosystem underscores the life sciences sector’s commitment to accelerating genomic discovery, improving diagnostics, and enabling precision healthcare.

Segmented market projections estimate that from 2025 to 2030, the sample preparation products market will grow by $1 billion, sequencing platforms and consumables by $4 billion, sequencing services by $1 billion, data analysis by $1 billion, storage by $0.4 billion, and management by $0.3 billion. The market is dominated by both global sequencing technology providers and specialized genomics solution companies focusing on high-throughput sequencing, integrated library preparation, advanced bioinformatics, automation, and scalable data analysis. Emphasis on sequencing accuracy, reproducibility, workflow efficiency, multi-omics compatibility, and compliance with clinical standards remains a key competitive factor.

Leading Company Driving the NGS-Based RNA-Sequencing Market
Illumina Inc. holds a leadership position in the global market, capturing a 6% share in 2025. Their extensive portfolio of sequencing systems and genomics solutions supports transcriptome profiling, gene expression analysis, biomarker discovery, and precision research across academic, clinical, and biopharmaceutical fields.

Top Industry Participants Operating in the NGS-Based RNA-Sequencing Market
The key players in this space include Illumina Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Agilent Technologies Inc., Eurofins Scientific SE, BGI Group, Novogene Corporation, Oxford Nanopore Technologies Ltd., Bio-Rad Laboratories Inc., GENEWIZ Inc., Takara Bio Inc., Zymo Research Corp., BaseClear B.V., GATC Biotech AG, Genotypic Technology Pvt. Ltd., Lexogen GmbH, Otogenetics Corporation, Genohub LLC, SeqLL LLC, GenXPro GmbH, and Macrogen Inc.

Market Concentration and Competitive Landscape Overview
The NGS-Based RNA-Sequencing market exhibits a fairly fragmented structure, with the top 10 players accounting for 18% of total market revenue in 2025. This moderate concentration reflects the high technological and scientific barriers to entry, including complex sequencing platform development, bioinformatics integration, specialized sample preparation, and scalable genomics infrastructure needs. Market leaders such as Illumina Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche Ltd. maintain strong positions through comprehensive sequencing portfolios, global laboratory networks, extensive research partnerships, and continuous improvements in sequencing chemistry and transcriptomics solutions. As the demand for precision medicine, biomarker discovery, single-cell analysis, and large-scale genomics research grows, these companies are leveraging innovation, strategic collaborations, and expanded laboratory capacities to secure competitive advantages.

Key Raw Material Suppliers Supporting the Market
Major suppliers of raw materials for the NGS-Based RNA-Sequencing market include Merck KGaA, Danaher Corporation, LGC Biosearch Technologies, Integrated DNA Technologies, New England Biolabs, Promega Corporation, Cytiva, PerkinElmer, Nippon Genetics Co., Ltd., TriLink BioTechnologies, Molecular Instruments, Biosearch Technologies, Azenta Life Sciences, ChemGenes Corporation, Jena Bioscience GmbH, Glen Research, Synbio Technologies, Bio-Synthesis Inc., and Vector Laboratories.

Primary Wholesalers and Distributors in the Market
Notable wholesalers and distributors serving the NGS-Based RNA-Sequencing market include Avantor Inc., VWR International, Fisher Scientific, Thomas Scientific, Cole-Parmer Instrument Company, Southern Labware, Biocompare, LabX Media Group, Medline Scientific, Genesee Scientific, CliniSciences Group, Bio-Strategy Ltd., DKSH Holding Ltd., Wako Pure Chemical Industries, SciMed Ltd., Cambridge Bioscience Ltd., SLS (Scientific Laboratory Supplies), Westburg B.V., and Labindia Instruments Pvt. Ltd.

Prominent End Users Driving Demand
Leading end users in this market encompass renowned research and clinical institutions such as Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Broad Institute, Wellcome Sanger Institute, St. Jude Children’s Research Hospital, The Jackson Laboratory, Genomics England, Beijing Genomics Institute, National Cancer Institute, Fred Hutchinson Cancer Center, Children’s Hospital of Philadelphia, Erasmus Medical Center, Charité – Universitätsmedizin Berlin, University of Oxford, Harvard Medical School, Stanford University School of Medicine, and University of California San Francisco.

Competitive Trends Shaping Market Evolution
Advancements in small RNA sequencing kits are transforming the landscape by enhancing workflow efficiency, boosting sequencing accuracy, and enabling high-quality small RNA expression profiling. For example, in October 2025, Lexogen GmbH introduced the miRVEL profiling small RNA-Seq library preparation kit, designed to simplify and optimize sequencing workflows. Its features include advanced adapter blocking technology, rapid library preparation, embedded unique dual indices, and compatibility with integrated RNA extraction and enrichment, all of which improve reproducibility, reduce sequencing artifacts, and support a wide range of transcriptomics research applications.

Strategies Adopted by Companies to Maintain Market Leadership
Key strategies currently being employed by leading companies include integrating single-cell RNA sequencing for detailed transcriptomic analysis, applying artificial intelligence to improve data interpretation and biomarker discovery, automating library preparation workflows to enhance throughput and reproducibility, forming strategic partnerships to broaden multi-omics and clinical genomics capabilities, and innovating products to advance long-read sequencing accuracy and transcript isoform detection.

This comprehensive overview highlights how technological innovation, strategic collaborations, and expanding applications across healthcare and research are driving exponential growth and shaping the future of the NGS-Based RNA-Sequencing market.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 30,000+ reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: marketing@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company“

Oliver Guirdham
The Business Research Company
+44 7882 955267
Visit us on social media:
LinkedIn
Facebook
X